Company news
In8bio, Inc. (NASDAQ:INAB) news
In8bio, Inc. news releases on 6ix. Latest, May 9, 2024: IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Press releases — page 2
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 8, 2024
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
April 29, 2024
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
April 23, 2024
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
April 8, 2024
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
March 13, 2024
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
February 13, 2024
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
January 3, 2024
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
December 10, 2023
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
December 10, 2023
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
December 6, 2023
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
November 19, 2023
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 8, 2023
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
November 5, 2023
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
November 2, 2023
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
November 1, 2023
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
October 11, 2023
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
September 28, 2023
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
September 25, 2023
IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
September 18, 2023
IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 9, 2023
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
August 7, 2023
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
June 4, 2023
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting
May 1, 2023
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
April 30, 2023
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
April 25, 2023
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
April 24, 2023
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023
April 23, 2023
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
April 16, 2023
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
April 10, 2023
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 29, 2023
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
March 15, 2023
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue
February 22, 2023
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
January 4, 2023
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
December 11, 2022
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
December 7, 2022
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 9, 2022
IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400
September 14, 2022
IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board
September 7, 2022
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
August 18, 2022
IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock
August 15, 2022
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock
August 10, 2022
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients
July 26, 2022
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
July 20, 2022
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
July 11, 2022
IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences
June 7, 2022
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
June 5, 2022
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
May 16, 2022